The company, established in 1999, is headquartered in Aurora, Colorado, and has a multinational presence. The GREVAX™ Universal Platform can design and produce vaccines in as little as 4 weeks once a pathogen has been identified. This platform is flexible and ideal for delivering vaccines against a wide variety of infectious diseases, including Pandemic Influenza strains, Anthrax, Dengue Fever, Malaria, Hepatitis C, RSV, Ebola, HPV, Plague, Tuberculosis, and other vaccine candidates.
Show More
Revenue: 500,000 - 999,999
Founded: 2007
Filing Number: 20071288624